Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital Authors: Gayathri Baburaj, Ananth Pai, Varun Kumar Sudha Gururaj, Satyanarayana Poojari, Mahadev Rao, Karthik S. Udupa Published: 2026 ABSTRACT ABSTRACTLung cancer continues to be the leading cause of morbidity and mortality associated with malignancies. Identifying prognostic factors is vital for improving survival outcomes. This study assessed the impact of clinical, demographic, and genetic factors on overall survival (OS) and progression‐free survival (PFS) in patients with non‐small cell lung cancer (NSCLC). A prospective cohort of 70 NSCLC patients was analyzed. Demographic and clinical data, including epidermal growth factor receptor (EGFR) mutation status and clinical response by RECIST 1.1 criteria, were assessed. Survival outcomes were estimated using the Kaplan–Meier method with log‐rank test. The median PFS and OS were 15 and 24 months, respectively. EGFR‐positive patients showed significantly longer survival than EGFR‐negative patients (PFS: 17 vs. 11 months, OS: not reached [NA] vs. 24 months). Brain metastases indicated poor OS (OS: 15 months vs. NA) but did not affect PFS. Patients with a partial response after one year exhibited improved overall survival (24‐month OS probability of 77.8%). EGFR mutation status, brain metastases, and clinical response are key predictors of survival in NSCLC patients. Integrating genetic screening, timely management of brain metastases, and early assessment may enhance personalized treatment and improve prognosis. Introduction Lung cancer continues to be the most commonly diagnosed cancer worldwide, constituting one in eight (12.4%) of total cases and one in five (18.7%) of total deaths, as reported by GLOBOCAN 2022 [1]. With 2.5 million new cases and over 1.8 million deaths, it is the leading cause of cancer morbidity and mortality [1]. According to the National Cancer Registry Programme (NCRP) report, the number of cases in India is anticipated to increase significantly in 2025, with 81,219 cases for males and 30,109 cases for females [2]. Non‐small cell lung cancer (NSCLC), the most prevalent subtype, accounts for approximately 85% of all lung cancer cases [3]. Several therapies are available for NSCLC, including surgical intervention, chemotherapy, radiation, targeted therapy, and immunotherapy. The traditional first‐line treatment for advanced NSCLC without targetable mutations is platinum‐based doublet chemotherapy with immunotherapy; nevertheless, the discovery of frequently mutated genes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and receptor tyrosine kinase (ROS1), along with the programmed death ligand 1 (PD‐L1) expression levels, has facilitated the advancement of targeted therapies, immunotherapies, and the implementation of routine testing for these mutations in NSCLC patients, thereby enhancing overall survival outcomes [4, 5]. In 2004, mutations in the EGFR gene were identified [6], and in 2015, the US Food and Drug Administration (FDA) approved EGFR tyrosine kinase inhibitors (EGFR‐TKIs), including gefitinib and afatinib, for first‐line treatment of EGFR‐mutated adenocarcinomas based on trials that demonstrated a reduction in size of NSCLC tumors that carried this mutation [6], enhanced outcomes, enhanced progression‐free survival, and a diminished risk of disease progression and mortality compared to prior conventional chemotherapy [4, 7, 8, 9, 10]. Despite advances in early detection and therapeutic strategies, the five‐year survival rate is still poor for NSCLC patients, from 68% in Stage IB patients to 0%–10% in Stage IVA/IVB patients, underscoring the urgent need for improved prognostic and therapeutic approaches [11, 12]. Besides the clinical stage, histological type, and molecular characterization of the tumor, other significant prognostic factors of NSCLC include the performance status of the patient [13], age [14], gender [15], smoking history [16], and metastasis [17]. The Response Evaluation Criteria in Solid Tumors (RECIST) was established in 2000 to evaluate variations in solid tumor size among patients receiving chemotherapy [18]. Based on imaging studies, the criteria assess the maximal diameters of target lesions. The initial guidelines were modified in 2009 (RECIST 1.1.) [19] to enhance target lesion definitions. RECIST criteria have progressively substituted World Health Organization (WHO) [20] criteria for assessing chemotherapy effects and have been associated with survival [21, 22]. Research on lung cancer clinical response based on RECIST and survival outcomes in India is limited, with little information available about clinical response and survival, as most research focuses on long‐term survival. Therefore, the current study aimed to identify significant prognostic factors by analyzing the survival outcomes of patients with NSCLC, focusing on those harboring EGFR mutations treated at our cancer hospital. Methodology Study Population A prospective cohort study was conducted among NSCLC patients in the Department of Medical Oncology, Kasturba Medical College & Hospital, Manipal from January 2019 to October 2023. All the NSCLC patients with EGFR mutation analysis, aged more than 18 and less than 75 years were included in the study using a convenience sampling method. HIV‐positive NSCLC patients and patients with critically ill conditions and major co‐morbidities and not willing to participate in the study were excluded. Additionally, patients having ≥ 1 quantifiable target lesion measurable by RECIST version 1.1 and a minimum 2‐year follow‐up were eligible for the survival analysis study. Outcome Measures Patient medical records were used to obtain clinical information including patient demographics and RECIST 1.1 response categories. Tumor response was assessed by experienced oncologists using RECIST 1.1. The clinical response was categorized as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to RECIST 1.1 [19], with efficacy assessments based solely on the first‐line treatment. CR was defined as the complete absence of all target and nontarget lesions with the exception of lymph nodes, which had to be < 10 mm short axis. PR was defined as a reduction of ≥ 30% in the sum of the diameters of target lesions (longest diameter for tumors, short axis for lymph nodes) compared with baseline measurements. SD is referred to as neither partial response nor progressive disease. PD was defined as ≥ 20% and ≥ 5‐mm increase in the sum of the target lesion measurements compared with the smallest sum recorded; the appearance of one or more new lesions; or unequivocal progression of nontarget lesions. Patient characteristics such as age, gender, histologic type of cancer, clinical stage, smoking history, medical comorbidities, metastasis, patient performance status according to Eastern Cooperative Oncology Group (ECOG) [23], mutation status, and treatment were observed. Treatment decisions were guided by established guidelines and institutional multidisciplinary tumor board recommendations. The choice of specific EGFR‐TKI and systemic therapy was based on mutation subtype, disease stage, patient comorbidities, and drug availability. Convenient blood or tissue samples from patients were sent to MedGenome Labs Ltd., India, for mutational analysis. The laboratory performed screening for EGFR mutations, ALK, and ROS‐1 alterations using droplet digital PCR (ddPCR) or next‐generation sequencing (NGS). Progression‐Free Survival (PFS) is defined as the time from the initiation of first‐line treatment to disease progression or death, whichever occurs first, as assessed according to RECIST version 1.1 criteria. Overall Survival (OS) is defined as the time from the initiation of first‐line treatment to death or the last day of observation. Statistical Analysis Survival probability was done using the Kaplan–Meier estimator. Statistical significance among the different groups was tested using a log‐rank test with a significance level of p < 0.05 and calculated 95% CI for PFS and OS outcomes. PFS and OS were assessed utilizing the Kaplan–Meier method. The log‐rank test was used to compare the PFS and OS between the groups. Additionally, Univariate Cox proportional hazards models were first applied to identify potential predictors of survival among patients with non‐small cell lung cancer. In the subsequent multivariable Cox regression, both clinically relevant and statistically significant variables were considered to estimate hazard ratios while adjusting for covariates. Analysis was carried out in RStudio (v 4.4.0) using survival and survminer packages. Results Demographic and Clinical Characteristics The total number of NSCLC patients during the study period was 155. Among them, only 70 were included for the survival analysis based on the inclusion criteria (follow‐up period of 2 years and EGFR mutation analysis). The study flowchart is described in Figure 1. The mean age of patients was 57.2 ± 9.26 years. Among 70 NSCLC patients included, 37 (52.86%) were male and 33 (47.14%) were female. Forty‐three (61.43%) were aged ≤ 60 and 27 (38.57%) were above 60 years old. The predominant histologic type identified was lung adenocarcinoma (90.00%) followed by squamous cell carcinoma (7.14%) and not otherwise specified (2.86%). Among these patients, clinical stage 4 was predominant (94.29%). EGFR mutation was positive in 33 (47.14%) patients and EGFR mutation was negative in 37 (52.86%) patients. Among the 33 patients with EGFR mutation‐positive status, 23 patients (69.7%) had exon 19 deletions, 10 patients (30.3%) had exon 21 L858R mutations, and 4 patients (12.1%) had T790M mutations. As first‐line EGFR‐TKI therapy, 26 (78.8%) patients received gefitinib, 4 (12.1%) afatinib, 2 (6.1%) osimertinib, and 1 (3.0%) erlotinib. A comparison of baseline demographics and clinical characteristics between EGFR‐mutant and EGFR‐wild‐type groups is provided in Table S1. Treatment regimens differed, with 51.52% of EGFR‐positive patients undergoing chemotherapy in combination with EGFR‐TKI, while 24.32% of EGFR‐negative patients received chemotherapy exclusively. Additional regimens comprised combinations of chemotherapy, radiotherapy, immunotherapy, targeted therapies, and TKIs (e.g., ALK/ROS1‐TKI), revealing distinct treatment patterns between EGFR‐positive and EGFR‐negative patients. The treatment regimen is classified into EGFR‐positive and negative patients and is provided in Table S2. Among 33 patients with EGFR mutation‐positive, 26 (78.79%) patients received gefitinib, 4 (12.12%) afatinib, 2 (6.06%) osimertinib, and 1 (3.03%) received erlotinib as EGFR‐TKI therapy as first‐line treatment. Among 37 EGFR‐negative patients, 4 (10.81%) patients were ROS1‐positive and 3 (8.11%) patients were ALK‐positive. Two patients received alectinib, and five patients received crizotinib TKIs targeting ALK and ROS1 alterations. Among seven patients who received immunotherapy, pembrolizumab (n = 3), atezolizumab (n = 2), and nivolumab (n = 2) were the immunotherapy treatment regimen. A total of seven patients received bevacizumab as targeted therapy. The most common chemotherapy regimens were paclitaxel‐ platinum‐based (43.24%) followed by pemetrexed‐ platinum‐based (41.89%). Surgery was done for five (6.75%) patients. Two (2.85%) patients received supportive care therapy alone. Of the 70 patients in the cohort, 35 (50%) had one or more comorbidities. The most prevalent comorbidity was hypertension, observed in 26 patients (74.29%), followed by diabetes mellitus in 18 patients (51.43%). The medical comorbidities of the patients are summarized in Table S3. According to RECIST 1.1, 19 (27.14%) patients had PR, 20 (28.57%) had SD, and 31 (44.29%) patients had PD. Study flowchart. EGFR, Epidermal growth factor receptor; IEC, Institutional ethics committee; NSCLC, Non‐small cell lung cancer. Analysis of Survival Outcomes Survival outcomes were assessed in a cohort of 70 patients to determine the influence of demographic, clinical, and genetic factors on PFS and OS. The median PFS and OS for the cohort were 15 months and 24 months, respectively (Figure 2). Among the factors examined, age, gender, smoking status, medical comorbidities, number of sites of metastasis, and ECOG performance status were not significantly associated with differences in survival outcomes. The study also demonstrated that smoking status did not have a significant effect on survival in patients with EGFR mutations. Although smokers exhibited marginally extended median PFS and OS, the disparity lacked statistical significance (Figure S1A–N). In the current study, the presence of brain metastasis at baseline, EGFR mutation status, and clinical response at 1 year emerged as critical determinants of survival. Kaplan–Meier curves of PFS and OS survival data in the total study population. (A) Kaplan–Meier curves of PFS survival data in the total study population (n = 70); (B) Kaplan–Meier curves of OS survival data in the total study population (n = 70). OS, Overall survival; PFS, Progression‐free survival. Patients without brain metastasis exhibited significantly improved overall survival compared to those with brain metastasis in Kaplan–Meier analysis. The median OS for patients without brain metastasis was not reached (NA), whereas it was 15 months for those with brain metastasis (p = 0.029) (Figure 3C). In contrast, the presence or absence of brain metastasis did not significantly impact PFS, with a median PFS of 16 months in patients without brain metastasis and 11 months in those with brain metastasis (p = 0.1). (Figure S1O). The study also analyzed PFS and OS in patients with brain metastases, considering their EGFR mutation status. Patients with EGFR mutations demonstrated a slightly improved median PFS compared to EGFR‐negative patients. Overall survival was extended in EGFR‐positive patients, with some patients surviving beyond 20 months, while EGFR‐negative patients demonstrated a median OS of 15 months. However, these differences were not of statistical significance (Figure S1M,N). Kaplan–Meier survival curves. (A) Comparison of progression‐free survival based on EGFR mutation, (B) Comparison of overall survival based on EGFR mutation, (C) Comparison of overall survival based on brain metastasis, (D) Comparison of overall survival based on clinical response. EGFR, Epidermal growth factor receptor; OS, Overall survival; PFS, Progression‐free survival. EGFR mutation status was strongly associated with improved survival outcomes. Patients with EGFR mutations demonstrated a median PFS of 17 months, compared to 11 months in EGFR‐negative patients (p = 0.00075) (Figure 3A). Similarly, EGFR‐positive patients demonstrated a significantly improved OS, with the median OS not reached (NA), compared to a median OS of 24 months in EGFR‐negative patients (p = 0.0056) (Figure 3B). The clinical response at 1 year was a significant predictor of survival. Patients demonstrating a partial response to treatment exhibited the most favorable survival outcomes, with a median OS not reached (24‐month OS probability of 77.8%). In contrast, patients with progressive disease at 1 year had significantly worse outcomes, with a median OS of 16 months (24‐month OS probability of only 15.4%) (p < 0.0001) (Figure 3D). These results highlight the prognostic importance of achieving a favorable clinical response in improving long‐term survival. Detailed survival outcome data are presented in Table 1. TABLE 1Analysis of survival outcomes.VariableTotal (%) (n = 70)Median PFS (months) p Median OS (months) p Age 0.0640.23Age ≤ 6043 (61.43)14NAAge > 6027 (38.57)1624 Gender 0.0780.17Male37 (52.86)1124Female33 (47.14)16NA Smoking status 0.290.67Yes36 (51.43)1124No34 (48.57)1624 Comorbidities 0.50.18Yes35 (50.00)1524No35 (50.00)1324 ECOG 0.820.240, 156 (80.00)15242, 314 (20.00)1624 Brain metastasis 0.10.029Yes13 (18.57)1115No57 (81.43)16NA No. of sites of metastasis a 0.940.27< 236 (53.73)1424≥ 231 (46.26)16NA EGFR mutation 0.000750.0056EGFR positive33 (47.14)17NAEGFR negative37 (52.85)1124 Response at 1 year NA< 0.0001Partial response19 (27.14)NANAStable disease20 (28.57)NANAProgressive disease31 (44.29)NA16Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NA, not available; OS, overall survival; PFS, progression‐free survival. a No of sites of metastasis, n = 67 (3 patients were excluded because no. of sites = 0). Analysis of survival outcomes. Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NA, not available; OS, overall survival; PFS, progression‐free survival. No of sites of metastasis, n = 67 (3 patients were excluded because no. of sites = 0). Univariate and Multivariable Cox Regression Model Univariate Cox proportional hazards models were first applied to identify potential predictors of survival among patients with non‐small cell lung cancer. Variables that showed relevance in the Kaplan–Meier survival analysis, along with clinically important variables such as smoking status, were included in the subsequent multivariable Cox regression model. This approach allowed estimation of hazard ratios while adjusting for covariates to better understand the independent impact of clinical, demographic, and genetic factors on overall survival. In the univariate analysis of patients with non‐small cell lung cancer, smokers had 2.9% lower hazard compared to non‐smokers (Hazard Ratio (HR) = 0.97, 95% Confidence Interval (CI) [0.44, 2.16]). EGFR mutation status was not significantly associated with overall survival (HR = 1.21, 95% CI [0.45, 3.23]). Similarly, brain metastasis was not significantly associated with overall survival (HR = 0.77, 95% CI [0.31, 1.94]). Compared to patients with stable disease, those with partial response showed an 85.4% lower hazard (HR = 0.15, 95% CI [0.03, 0.62]), while patients with progressive disease experienced a 5.4‐fold higher hazard (HR = 5.41, 95% CI [2.16, 13.57]). Among these, treatment response (partial response and progressive disease) was a statistically significant predictor of survival. Smoking status, EGFR mutation status, and brain metastasis were not statistically significant in the univariate analysis. In patients with non‐small cell lung cancer, adjusted hazard ratios from the multivariable cox regression model indicated that non‐smokers had 2.6% lower hazard compared to smokers (Adjusted Hazard Ratio (AHR) = 0.97, 95% CI [0.44, 2.17]). EGFR mutation status was not significantly associated with overall survival (AHR = 1.20, 95% CI [0.45, 3.23]). Similarly, brain metastasis was not significantly associated with overall survival (AHR = 0.77, 95% CI [0.31, 1.95]). Compared to patients with stable response to treatment, those showing partial response demonstrated 63.3% lower hazard (AHR = 0.37, 95% CI [0.07, 2.06]), while those with progressive disease experienced approximately threefold higher hazard (AHR = 3.04, 95% CI [0.96, 9.60]). The likelihood ratio test, χ 2(5) = 17.89, p = 0.003, suggests that the overall model fit was statistically significant. The concordance index value of 0.777 (SE = 0.041) indicated that the model correctly ranked the survival times for 77.7% of patient pairs. This suggests that the model demonstrated good discriminative ability in distinguishing patients based on hazard. Detailed univariate and multivariable Cox regression tables are provided in Table S4. Discussion The current study evaluates the clinical response and survival outcomes of advanced NSCLC. The data showed a median PFS of 15 months and a median OS of 24 months. Although the prognostic impact of EGFR mutation status, brain metastases, and RECIST‐defined response has been reported previously, the present study provides real‐world evidence from a prospective single‐center Indian cohort with integrated assessment of molecular status, treatment response, and clinical prognostic factors within the same population. While our findings are largely consistent with prior regional studies [24, 25], differences in median PFS and OS may reflect variation in mutation subtype distribution, treatment sequencing, and access to subsequent lines of therapy. In this cohort, neither age nor gender demonstrated a significant association with survival outcomes. Females exhibited a trend of poorer PFS relative to males (p = 0.078), which is inconsistent with the majority of epidemiological and clinical studies indicating enhanced survival rates in women with NSCLC [11, 26]. This finding may be due to the limited sample size, treatment variability, or residual confounding associated with molecular subtype and clinical characteristics. While > 60‐year‐old patients had slightly longer median PFS than younger patients with no statistically significant difference observed between the two cohorts. Similarly, while females exhibited a pattern towards better survival than males, this variation did not achieve statistical significance. These findings are consistent with prior research that suggests that, although age and gender may affect the biology of cancer and the response to treatment, they may not be reliable indicators of survival when other variables, such as genetic alterations and disease features, are taken into account [14, 27, 28]. In the cohort we studied, PFS and OS were not significantly affected by smoking status or the existence of medical comorbidities. The association between smoking status and survival was not statistically significant (p = 0.29). The relatively stronger association observed for gender compared with smoking suggests that the prognostic impact of sex warrants further investigation in larger, adequately powered studies. The results align with previous research highlighting the complicated impact of smoking on cancer prognosis, which is sometimes overshadowed by factors particular to the disease and genetics [28, 29]. Previous studies have reported poorer survival outcomes among smokers with NSCLC compared with never‐smokers, potentially due to higher tumor mutational burden, treatment resistance, and increased comorbidity burden [16, 30]. However, the lack of a significant association in the present study may reflect limited sample size and confounding by molecular subtype. It appears that comorbidities do not significantly affect survival outcomes in our cohort, despite 50% of patients having one or more comorbidities. It's also feasible that these patients' comorbidity management was effective enough to reduce its likely impact on survival as Grose et al. demonstrated that proactive, integrated care approaches can substantially mitigate comorbidity impact on cancer outcomes [31]. The gap between our findings and existing literature highlights the necessity of thorough comorbidity evaluation in oncology research, as Lüchtenborg et al. [32] demonstrated that the impact of comorbidities on lung cancer survival significantly differs across various healthcare environments and patient demographics. In contrast, a study by Islam et al. [33] concluded that various comorbid conditions were significantly linked to lung cancer survival across different stages. The prognostic influence of metastatic site burden on OS and PFS in NSCLC has been the subject of recent investigations. The findings have been inconsistent, with some suggesting that there is no significant difference in outcomes between patients with two or more metastatic sites and those with fewer than two. Our study found no significant difference in OS was observed between patients with fewer than two metastatic sites and those with two or more sites. The findings align with prior research indicating that metastases were not associated with survival time, but rather with driving mutations such as EGFR‐positive mutations [17]. In contrast, there is a correlation between a higher number of metastatic organ sites (1, 2, or 3) and a lower chance of survival. Survival for patients with three metastasized organ sites was found to be poor comparable to that of individuals with four or more metastases [34]. The brain is the most prevalent site for NSCLC metastases, and 30% of individuals with NSCLC have brain metastases [35]. Prognosis is poor for patients with advanced NSCLC and brain metastases. For NSCLC with brain metastases, the median OS is 4–5 months or 4–6 weeks, depending on whether treatment is received or not [36]. Patients with brain metastasis showed lower 24‐month overall survival in unadjusted analysis, but this was not significant in the multivariable analysis. Although prior studies identify brain metastasis as an adverse prognostic factor, it was not an independent predictor in our cohort [34, 36]. The ineffective management of brain metastases and the limited availability of treatment options likely contribute to the poor outcomes observed in these patients [37]. In this study, EGFR‐TKI selection was based on EGFR mutation status rather than the presence of brain metastases. The transition to osimertinib for the treatment of brain metastases was not routinely performed. Intracranial care, encompassing radiotherapy or surgery, was individualized. Although osimertinib has superior intracranial efficacy and is currently preferred in this setting, its use in our cohort was limited [38]. In the study, patients with an ECOG performance status of 0–1 exhibited a median PFS of 15 months, which was slightly lower than that of patients with a performance status of 2–3; however, this difference was not statistically significant. In contrast, multiple studies have demonstrated a significant impact of performance status on PFS in patients with NSCLC, indicating patients with a better ECOG score (0–1) exhibited significantly better PFS compared to those with lower scores (2–3) [27, 28, 39, 40]. This discrepancy may be attributable to the small sample size, the predominance of patients with ECOG 0–1, and treatment heterogeneity, which may have reduced the discriminatory power of ECOG in this study [41]. In India, EGFR mutation testing has become more prevalent in the diagnostic evaluation of advanced NSCLC, especially in tertiary care centers. Nonetheless, access to routine molecular testing varies among institutions due to financial and infrastructural limitations. The prevalence of EGFR mutations in Indian NSCLC cohorts varies across studies, with reported rates around 23% in large cohorts and higher in selected populations. This finding underscores the importance of routine upfront EGFR testing for determining targeted therapy [42, 43]. In this cohort, EGFR‐positive patients exhibited significantly longer PFS and OS compared to EGFR‐negative patients, suggesting that the EGFR mutation appears to be associated with favorable survival, although findings should be interpreted with caution due to sample size, single‐center design, and treatment variability. In NSCLC patients, where targeted treatments for EGFR mutations have revolutionized treatment, this result supports the well‐established importance of EGFR mutations as favorable prognostic markers. In this study, EGFR‐positive patients had a median PFS of 17 months, notably longer than the 11 months observed in EGFR‐negative patients. Prior research from several studies demonstrated a significant PFS benefit provided by EGFR‐TKIs [8, 9, 44, 45]. In our research, tumor response to treatment was evaluated using RECIST 1.1 criteria. Achieving an early and positive response to treatment is crucial, as evidenced by the substantial correlation seen between survival outcomes and clinical response at 1 year. Overall survival was significantly impacted, according to a one‐year evaluation of clinical response. With a 24‐month survival probability of 77.8%, patients who experienced a partial response had the best outcomes. On the other hand, the prognosis was considerably poorer for individuals whose condition progressed, with a survival probability of 15.4% at 24 months. The study highlights the need to assess treatment efficacy early on and the advantages of modifying therapy approaches in response to early response markers. The significant differences in survival rates based on clinical response emphasize the dynamic nature of cancer treatment and the necessity for regular assessment and modification of therapy. The study results align with prior research indicating a significant association between RECIST and overall survival (OS) [27]. Limitations of the Study This research has certain limitations. Data collection and analysis are limited to a single center with a relatively small sample size, thus constraining the generalizability of the results. The study exclusively involved patients who underwent EGFR mutation analysis, limiting its representation of the wider NSCLC population. Including ALK/ROS1 mutations into the EGFR‐negative cohort may introduce variability, making it difficult to distinguish the distinctive prognostic impacts of these mutations. Furthermore, other actionable mutations such as KRAS and BRAF were not systematically screened during the study period, largely due to the high cost of extended molecular testing. This may underestimate the broader molecular heterogeneity of NSCLC. Additionally, due to limited numbers in each EGFR mutation subtype group, subtype‐specific survival analyses could not be performed. As different EGFR mutations (e.g., exon 19 deletions, exon 21 L858R, T790M) are known to have distinct therapeutic sensitivity and prognosis, larger studies are needed to explore these subtype‐specific outcomes. Tumor response was assessed by experienced oncologists using standardized RECIST 1.1 imaging protocols; however, readers were not formally blinded and inter‐observer variability was not assessed, which may introduce bias in response evaluation. Variations in treatment regimens and sequencing, including the use of different EGFR‐TKIs and chemotherapy or immunotherapy regimens, may have influenced outcomes. Treatment selection was based on clinical factors and physician discretion, which limits direct comparison between treatment groups. Consequently, subgroup analyses evaluating outcomes based on treatment type (e.g., different generations of EGFR‐TKIs, chemotherapy) and combination strategies were not feasible. The use of a convenience sampling strategy may restrict the diversity of the study population. The 2‐year follow‐up duration for survival analysis may be inadequate to encompass long‐term survival outcomes. Conclusion The study highlights the significance of EGFR mutation status, presence of brain metastases at baseline, and clinical response at 1 year in predicting survival outcomes in NSCLC patients. Patients with EGFR mutation exhibited longer PFS and OS, suggesting the necessity for regular genetic screening to incorporate TKI therapy. Brain metastases were not significantly associated with overall survival in the multivariable analysis. The early clinical response, evaluated using RECIST criteria, exhibited a strong correlation with survival outcomes, emphasizing the necessity for frequent clinical response assessments to enhance therapy regimens. The research highlights the necessity for personalized therapy strategies that integrate genetic screening, proactive management of brain metastases, and early evaluation of treatment effectiveness to improve survival outcomes in NSCLC patients. Author Contributions G.B. and A.P. wrote the manuscript; G.B., A.P., M.R., and K.S.U. designed the research; G.B. and A.P. performed the research; G.B., V.K.S.G., and S.P. analyzed the data. Funding The authors have nothing to report. Ethics Statement The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Kasturba Medical College (KMC) and Kasturba Hospital (KH) Institutional Ethics Committee (IEC No:750/2019) and Clinical Trials Registry—India (CTRI) (CTRI/2019/12/022284). Informed consent was obtained from all subjects involved in the study. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1. cts70579‐sup‐0001‐Supplementary‐Figures.pdf. Table S1. Baseline demographic and clinical characteristics of patients with EGFR‐mutant and EGFR‐wild‐type NSCLC. Table S2. Treatment regimen of enrolled patients. Table S3. Distribution of Co‐morbidities in the Cohort. Table S4A. Results of Univariate Cox Regression Model for Non‐Small Cell Lung Cancer patients. Table S4B. Results of Multivariable cox regression model for Non‐Small Cell Lung Cancer patients.